Back to discover

Protein / target

Glucose-6-phosphate 1-dehydrogenase

Encoded byG6PDP11413Homo sapiensSwiss-Prot
Small-molecule tractable
Druggability
Structure with Ligand
1
Research papers

Protein at a glance

Biological role

Glucose-6-phosphate dehydrogenase

Strongest disease association

Anemia

Via encoding gene G6PD · Genetic evidence · score 0.99

Research activity

Emerging research

1 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Catalyzes the rate-limiting step of the oxidative pentose-phosphate pathway, which represents a route for the dissimilation of carbohydrates besides glycolysis.

View complete UniProt function annotation

Catalyzes the rate-limiting step of the oxidative pentose-phosphate pathway, which represents a route for the dissimilation of carbohydrates besides glycolysis. The main function of this enzyme is to provide reducing power (NADPH) and pentose phosphates for fatty acid and nucleic acid synthesis. Also catalyzes the conversion of NAADPH, which is produced by enzymes such as DUOX1, DUOX2 and NOX5 from NAADP and promotes Ca(2+) signaling during T cell activation, back to NAADP (PubMed:34784249)

Subcellular location

Cytoplasm, cytosolMembrane
Domains and Gene Ontology detail (30)

Gene Ontology

  • Ccytoplasm
  • Ccytoplasmic side of plasma membrane
  • Ccytosol
  • Cextracellular exosome
  • Cmembrane
  • FD-glucose binding
  • Fglucose-6-phosphate dehydrogenase activity
  • Fidentical protein binding
  • FNADP binding
  • Fprotein homodimerization activity
  • Pcellular response to oxidative stress
  • Pcholesterol biosynthetic process

515 aa · 59 kDa · 3 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Lipid & lipoprotein metabolismUniProt · GOIon channel gatingGO
View supporting evidence

Lipid & lipoprotein metabolism

  • ·Catalyzes the rate-limiting step of the oxidative pentose-phosphate pathway, which repre…
  • ·cholesterol biosynthetic process
  • ·lipid metabolic process

Ion channel gating

  • ·positive regulation of calcium ion transmembrane transport via high voltage-gated calciu…

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene G6PD

Gene-level evidence surfaced through the gene G6PD that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Anemia
0.99Well supported

Genetic evidence dominant · Open Targets 0.78

Glucosephosphate Dehydrogenase Deficiency
0.94Well supported

Genetic evidence dominant · Open Targets 0.69

Genetic Diseases, Inborn
0.87Well supported

Genetic evidence dominant · Open Targets 0.53

Infections
0.66Moderately supported

Genetic literature evidence dominant · Open Targets 0.49

Neoplasms
0.42Preliminary

Pathway evidence dominant · Open Targets 0.28 · no direct causal or clinical evidence

View evidence synthesis (5)
AnemiaWell supported
0.99
agreement 0.871.00
Genetic84%Animal model9%Literature7%Genetic literaturedup

Open Targets aggregate 0.78 · 3 independent evidence families · 1 not counted as duplicate

Glucosephosphate Dehydrogenase DeficiencyWell supported
0.94
agreement 0.801.00
Genetic87%Literature13%Genetic literaturedup

Open Targets aggregate 0.69 · 2 independent evidence families · 1 not counted as duplicate

Genetic Diseases, InbornWell supported
0.87
agreement 0.731.00
Genetic98%Literature2%

Open Targets aggregate 0.53 · 2 independent evidence families

InfectionsModerately supported
0.66
agreement 0.510.81
Genetic literature83%Literature17%

Open Targets aggregate 0.49 · 2 independent evidence families

NeoplasmsPreliminary
0.42
agreement 0.240.60
Pathway72%Literature28%

Open Targets aggregate 0.28 · 2 independent evidence families · no direct causal or clinical evidence

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Anemia0.78
Glucosephosphate Dehydrogenase Deficiency0.69
Genetic Diseases, Inborn0.53
Infections0.49
Neoplasms0.28

Tractability

Small moleculesEmerging

Feasibility evidence (structure with ligand and high-quality ligand) — no clinical-stage drug of this modality recorded.

AntibodiesEmerging

Feasibility evidence (uniprot loc high conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (database ubiquitination and half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (8)
SM · Structure with LigandSM · High-Quality LigandSM · High-Quality PocketSM · Druggable FamilyAB · UniProt loc high confPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Safety-related annotations

unknown hemolysisClinPGxpulmonary damageClinPGxvarying degree of G6PD deficient red blood cellsClinPGxmethemoglobinemia and/or hemolysisClinPGxrequiring a blood transfusionClinPGxsurvival of red blood cellsClinPGxhemolysis or hemolytic anemiaClinPGxunknown rate of red blood cell survivalClinPGxmoderate anemiaClinPGxhemolysis and severe/unsafe hemoglobin decreasesClinPGxhemolytic anemiaClinPGxvarying degree of G6PD deficient red blood cells and an unknown hemolytic anemiaClinPGx

Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.

Research activity

1 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Shah SS · Frontiers in immunology · 2024

Recent

The global role of G6PD in infection and immunity.

Shah SS · Frontiers in immunology · 2024

Europe PMC papers linked directly to this protein.